Expression Analysis of MiR-21, MiR-205, and MiR-342 in Breast Cancer in Iran

Savad, Shahram; Mehdipour, Parvin; Miryounesi, Mohammad; Shirkoohi, Reza; Fereidooni, Forouzandeh; Mansouri, Fatemeh; Modarressi, Mohammad Hossein

doi:10.7314/apjcp.2012.13.3.873

Cited by 52 publications

(36 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…78 Interestingly, expression of miR-205 is downregulated in breast cancer cell lines that belong to claudin-low subtype, which is known to be associated with high epithelial-mesenchymal transition, 79 as well as in triple-negative breast cancer human samples. 74,80 Of note, the commonly used triple-negative inflammatory breast cancer cell line SUM149, unlike the claudin-low subtype of breast cancer cell lines, does not contain a detectable mesenchymal subpopulation 81,82 and demonstrates a much higher expression level of miR-205 than the triple-negative breast cancer cell lines with a mesenchymal phenotype. 79 Consistent with its potential role in tumor metastasis demonstrated in vitro, a recent miRNA expression profiling study of human metastatic cancers demonstrated miR-205 downregulation in metastatic breast cancer in lymph nodes compared with primary breast cancers, but not in metastatic cancers from the colon, bladder, or lung.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

et al. 2016

View full text Add to dashboard Cite

Inflammatory breast cancer is the most aggressive form of breast cancer. Identifying new biomarkers to be used as therapeutic targets is in urgent need. Messenger RNA expression profiling studies have indicated that inflammatory breast cancer is a transcriptionally heterogeneous disease, and specific molecular targets for inflammatory breast cancer have not been well established. We performed microRNA expression profiling in inflammatory breast cancer in comparison with locally advanced noninflammatory breast cancer in this study. Although many microRNAs were differentially expressed between normal breast tissue and tumor tissue, most of them did not show differential expression between inflammatory and noninflammatory tumor samples. However, by microarray analysis, quantitative reverse transcription PCR, and in situ hybridization, we showed that microRNA-205 expression was decreased not only in tumor compared with normal breast tissue, but also in inflammatory breast cancer compared with noninflammatory breast cancer. Lower expression of microRNA-205 correlated with worse distant metastasis-free survival and overall survival in our cohort. A small-scale immunohistochemistry analysis showed coexistence of decreased microRNA-205 expression and decreased E-cadherin expression in some ductal tumors. MicroRNA-205 may serve as a therapeutic target in advanced breast cancer including inflammatory breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…miR-205 was significantly underexpressed in triple-negative primary breast cancers when compared with tumor-associated normal samples. Both miR-205 and miR-342 have been proposed as potential biomarkers for diagnosis of TNBC (35). It has been previously shown that miR125b expression is lower in TNBC tumor tissue when compared with adjacent normal tissue, and has been related with chemoresistance (36).…”

Section: Mirna Expression Analysismentioning

confidence: 99%

Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications

et al. 2015

View full text Add to dashboard Cite

Better knowledge of the biology of breast cancer has allowed the use of new targeted therapies, leading to improved outcome. High-throughput technologies allow deepening into the molecular architecture of breast cancer, integrating different levels of information, which is important if it helps in making clinical decisions. microRNA (miRNA) and protein expression profiles were obtained from 71 estrogen receptor-positive (ER þ ) and 25 triple-negative breast cancer (TNBC) samples. RNA and proteins obtained from formalin-fixed, paraffin-embedded tumors were analyzed by RT-qPCR and LC/MS-MS, respectively. We applied probabilistic graphical models representing complex biologic systems as networks, confirming that ER þ and TNBC subtypes are distinct biologic entities. The integration of miRNA and protein expression data unravels molecular processes that can be related to differences in the genesis and clinical evolution of these types of breast cancer. Our results confirm that TNBC has a unique metabolic profile that may be exploited for therapeutic intervention. Cancer Res; 75(11); 2243-53. Ó2015 AACR.

show abstract

“…miR-205 was found to be up-or down-regulated in breast cancer and it may function as either a tumor suppressor or an oncogene. As mentioned above, mir-205 can function through both in normal development and cancer initiation, progression and metastasis (Savad et al, 2012). Its expression was found to be restricted to the myoepithelial/basal cell section of normal mammary ducts and lobules (Sempere et al, 2007).…”

Section: Mir-205 In Breast Cancermentioning

confidence: 92%